WASHINGTON — Drug makers dodged more than $1.3 billion in Medicaid drug rebates between 2012 and 2016 because they inappropriately or mistakenly miscategorized brand-name products as generics, which qualify for lower rebates.

Some $1.17 billion of that figure was associated with miscategorizations for just two drugs, according to a new report from the Health and Human Services Department’s independent inspector general, which did not name the products or their manufacturers. Had the 10 most expensive of the drugs been classified appropriately, state Medicaid programs would have saved that $1.3 billion figure, the report said. Instead, they collected just $199 million for those drug rebates.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy